Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
732.30
>-0.01(-4.76%)
At close: 4:00 PM EST
732.30
>-0.01(-4.76%)
Day’s Range― - ―
52-Week Range374.00 - 3,900.00
Previous CloseN/A
Volume13.23M
Average Volume (3M)1.04M
Market Cap
₪22.44M
Enterprise Value51.64
Total Cash (Recent Filing)₪8.54M
Total Debt (Recent Filing)₪71.00K
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
Aug 27, 2026EPS Estimate
-50.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthVery low leverage reduces near-term funding risk and provides financial flexibility to support clinical programs, licensing talks, or M&A. That optionality makes it easier to fund trials or bridge milestones without immediate insolvency pressure, a durable structural benefit.
High Gross MarginsExtremely high gross margins imply favorable unit economics typical for small-molecule drugs and strong operating leverage once commercialized or licensed. This structural margin advantage can support R&D and SG&A absorption and improve long-term profitability potential if revenues scale.
Reduced Cash Burn TrendA year‑over‑year reduction in free cash burn signals improving cost control or program timing, extending runway and lowering immediate financing needs. Sustained lower burn over months enhances the company's ability to advance trials and negotiate partnerships without urgent dilution.
Bears Say
Declining RevenuesPersistently tiny and declining revenues show the company lacks commercial products and cannot self-fund development. Structural top-line weakness increases dependence on external capital or partners to sustain operations and limits scalability until regulatory approvals or licensing occur.
Large And Worsening LossesOngoing, growing operating and net losses combined with consistently negative cash generation erode reserves and force repeated financing or dilutive transactions. This persistent cash deficit constrains strategic flexibility and heightens execution risk over the medium term.
Negative Returns / Equity ErosionSharply negative ROE and materially fluctuating, lower equity indicate capital erosion from losses and possible past dilution. This raises the likelihood of future financing events, making shareholder dilution and capital‑structure instability a durable risk to long‑term value.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 374.00 and its highest was 3900.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪22.44M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 33 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Mar 26, 2026. The company reported -917.366 earnings per share for the quarter, missing the consensus estimate of -21.513 by -895.854.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate is -50.71.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 4,285,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -917.366 in its last earnings report, missing expectations of -21.513. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.